Candriam SCA’s Amicus Therapeutics FOLD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | – | Sell |
-799,823
| Closed | -$9.42M | – | 701 |
|
|
2024
Q1 | $9.42M | Buy |
799,823
+245,944
| +44% | +$3.15M | 0.06% | 264 |
|
|
2023
Q4 | $7.86M | Sell |
553,879
-25,000
| -4% | -$284K | 0.05% | 284 |
|
|
2023
Q3 | $7.04M | Sell |
578,879
-115,000
| -17% | -$1.48M | 0.05% | 266 |
|
|
2023
Q2 | $8.72M | Hold |
693,879
| – | – | 0.06% | 262 |
|
|
2023
Q1 | $7.08M | Hold |
693,879
| – | – | 0.05% | 304 |
|
|
2022
Q4 | $8.47M | Buy |
693,879
+25,000
| +4% | +$281K | 0.06% | 306 |
|
|
2022
Q3 | $6.98M | Sell |
668,879
-170,000
| -20% | -$1.89M | 0.05% | 333 |
|
|
2022
Q2 | $9.01M | Buy |
+838,879
| New | +$6.91M | 0.07% | 239 |
|
|
2021
Q2 | – | Sell |
-615,124
| Closed | -$13.6M | – | 916 |
|
|
2021
Q1 | $13.6M | Hold |
615,124
| – | – | 0.11% | 201 |
|
|
2020
Q4 | $14.2M | Sell |
615,124
-156,464
| -20% | -$3.2M | 0.11% | 203 |
|
|
2020
Q3 | $10.9M | Buy |
771,588
+30,000
| +4% | +$437K | 0.1% | 218 |
|
|
2020
Q2 | $11.2M | Sell |
741,588
-187,912
| -20% | -$2.29M | 0.12% | 201 |
|
|
2020
Q1 | $8.85M | Hold |
929,500
| – | – | 0.1% | 237 |
|
|
2019
Q4 | $9.05M | Sell |
929,500
-46,500
| -5% | -$426K | 0.1% | 239 |
|
|
2019
Q3 | $7.83M | Buy |
976,000
+90,000
| +10% | +$977K | 0.1% | 234 |
|
|
2019
Q2 | $11M | Buy |
886,000
+150,000
| +20% | +$1.9M | 0.14% | 177 |
|
|
2019
Q1 | $10M | Buy |
736,000
+140,000
| +23% | +$1.71M | 0.13% | 188 |
|
|
2018
Q4 | $5.71M | Buy |
596,000
+65,000
| +12% | +$714K | 0.09% | 257 |
|
|
2018
Q3 | $6.42M | Buy |
531,000
+70,000
| +15% | +$979K | 0.09% | 269 |
|
|
2018
Q2 | $7.2M | Sell |
461,000
-4,000
| -0.9% | -$60.5K | 0.11% | 221 |
|
|
2018
Q1 | $6.99M | Sell |
465,000
-75,400
| -14% | -$1.15M | 0.12% | 218 |
|
|
2017
Q4 | $7.78M | Buy |
540,400
+58,000
| +12% | +$797K | 0.13% | 191 |
|
|
2017
Q3 | $7.28M | Sell |
482,400
-314,500
| -39% | -$4.16M | 0.13% | 203 |
|
|
2017
Q2 | $8.03M | Buy |
796,900
+70,000
| +10% | +$563K | 0.15% | 173 |
|
|
2017
Q1 | $5.18M | Sell |
726,900
-135,000
| -16% | -$854K | 0.1% | 245 |
|
|
2016
Q4 | $4.28M | Sell |
861,900
-125,000
| -13% | -$865K | 0.1% | 238 |
|
|
2016
Q3 | $7.3M | Buy |
986,900
+277,000
| +39% | +$1.87M | 0.18% | 144 |
|
|
2016
Q2 | $3.88M | Buy |
709,900
+90,000
| +15% | +$629K | 0.1% | 221 |
|
|
2016
Q1 | $5.21M | Sell |
619,900
-144,100
| -19% | -$1.02M | 0.13% | 184 |
|
|
2015
Q4 | $7.41M | Sell |
764,000
-180,000
| -19% | -$1.62M | 0.2% | 129 |
|
|
2015
Q3 | $13.2M | Sell |
944,000
-226,000
| -19% | -$3.54M | 0.32% | 87 |
|
|
2015
Q2 | $16.6M | Sell |
1,170,000
-180,000
| -13% | -$2.16M | 0.34% | 73 |
|
|
2015
Q1 | $14.7M | Buy |
1,350,000
+655,000
| +94% | +$5.77M | 0.3% | 88 |
|
|
2014
Q4 | $5.78M | Buy |
+695,000
| New | +$4.77M | 0.12% | 208 |
|
Other funds holding FOLD
PA
ACA
RG
Candriam SCA's FOLD Position: Q2 2024 in Review
Candriam SCA sold out of Amicus Therapeutics (FOLD) in Q2 2024, closing a stake of 799,823 shares — an estimated $9.42M sold.
Candriam SCA first reported a position in FOLD in Q4 2014 and held it in 34 quarters. The position peaked at $16.6M in Q2 2015. 258 funds tracked by Wall St. Rank hold FOLD as of Q2 2024.
- Candriam SCA reported no remaining Amicus Therapeutics position as of Q2 2024 after selling out during the quarter.
- Candriam SCA sold 799,823 Amicus Therapeutics shares in Q2 2024, an estimated $9.42M.
- Candriam SCA first reported a position in Amicus Therapeutics in Q4 2014 and held it in 34 quarters.
- Candriam SCA's Amicus Therapeutics position peaked at $16.6M in Q2 2015.
- 258 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q2 2024.
Based on Candriam SCA's 13F filing for Q2 2024, filed 5 Aug 2024.